论文部分内容阅读
AMI的静脉溶栓治疗目的是使冠状动脉再通,最大限度地挽救缺血濒死的心肌,维护心脏功能,降低病死率。自1998年1月至2000年12月,我院应用小剂量重组组织型纤溶酶原激活剂(rt-PA)和尿激酶静脉溶栓治疗116例AMI患者,比较两者的疗效及安全性,现报道如下。 1 资料与方法 1.1 病例选择 本院冠心病监护病房(CCU)1998年1月至2000年12月收治并确诊116例AMI患者,随机分为rt-PA组和UK组,均
The purpose of intravenous thrombolysis AMI is to make the coronary recanalization to maximize the rescue of ischemic dying myocardium, maintain cardiac function and reduce mortality. From January 1998 to December 2000, 116 patients with AMI were treated with low-dose recombinant tissue-type plasminogen activator (rt-PA) and urokinase intravenous thrombolysis in our hospital. The curative effect and safety of both Now reported as follows. 1 Materials and Methods 1.1 Case Selection Our hospital coronary heart care unit (CCU) from January 1998 to December 2000 admitted and diagnosed 116 cases of AMI patients were randomly divided into rt-PA group and UK group, both